For over 78 years, Bioplus has served the pharmaceutical industry with high-quality products, services, and technology. While continuing to build our global partnerships in Contract Manufacturing and EU / ANZ pharma generic pharmaceuticals, we are increasingly focused on utilizing our advanced skill set in Biotechnology. Today we are a late-stage clinical phase company with 2 programs for large global unmet needs both of which are Clinical phase 3 ready.
We intend to partner with leading companies regionally or globally to optimize product market access. We also have a rich pipeline of pre-clinical programs.
We expect the next 5 years to be of significant growth as our global blockbuster Novel therapeutics come to market. We continue to invest substantially in R&D and Clinical Development while supporting CAPEX in Capacity and Capability expansion. We are scientifically curious, focused on our targeted clinical development, and are enjoying the journey to learn more and contribute to the health and well-being of all global citizens.
Chairman & CEO
Vice President & CFO
Dosage Forms | Capacity |
---|---|
Tablets | 7 Billion / Year |
Capsules | 630 Million / Year |
Blend/ Powders | 2000 Metric Tons / Year |
Sachets | 190 Million Sachets / Year |
Liquids (2 oz) | 72 Million Bottles / Year |
Liquids (17 oz) | 20 Million Bottles / Year |
Effervescent | 9.72 Million Tubes / Year |
High Potency Tablets | 100 million / Year |
API | Capacity |
---|---|
Peptides & Proteins | 120 KGs / year |
Fermentation | 50,000 Litres |
Synthetic Chemistry | 120,000 Litres |
Manufacturing Sites | Site 1 | Site 2 | Site 3 |
---|---|---|---|
Land Area | 70,000 Ft² | 70,000 Ft² | 15 acres |
Type | EU / TGA / Health Canada GMP Pharma | Supplements – solid oral dosage forms | Liquid Dosage Form, R&D, API / Biotech |